disability

Tocilizumab found to be effective, safe for NMOSD: Meta-analysis

Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease disability while being generally safe, according to a meta-analysis. The study, “Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety,” was published in the journal…

AIMP1 Protein May Be Promising Biomarker for NMOSD, Study Shows

People with neuromyelitis optica spectrum disorder (NMOSD) have elevated levels of the pro-inflammatory protein AIMP1 in the bloodstream, and higher levels seem to correlate with worse disability, a study showed. These AIMP1 levels dropped markedly after anti-inflammatory therapy, but still remained higher among patients in remission than in people…

Case Report Describes NMOSD Rebound During Pregnancy

A young woman had a rebound of neuromyelitis optica spectrum disorder (NMOSD) toward the end of her pregnancy, for which she underwent plasma exchange and took steroids, according to a report from researchers in the U.S. Because treatment with plasma exchange and steroids did not work well enough, the…